WO2024254448A3 - Boronate prodrug nanoformulations in disease treatments - Google Patents

Boronate prodrug nanoformulations in disease treatments Download PDF

Info

Publication number
WO2024254448A3
WO2024254448A3 PCT/US2024/033004 US2024033004W WO2024254448A3 WO 2024254448 A3 WO2024254448 A3 WO 2024254448A3 US 2024033004 W US2024033004 W US 2024033004W WO 2024254448 A3 WO2024254448 A3 WO 2024254448A3
Authority
WO
WIPO (PCT)
Prior art keywords
boronate
amb
nanoplatform
nanoformulations
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/033004
Other languages
French (fr)
Other versions
WO2024254448A2 (en
Inventor
Dandan Guo
Juntao Luo
Changying SHI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of WO2024254448A2 publication Critical patent/WO2024254448A2/en
Publication of WO2024254448A3 publication Critical patent/WO2024254448A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Amphotericin B (AmB) is the gold standard for treatment of life-threatening systemic fungal infections. To develop cost-effective AmB formulations with reduced toxicity, embodiments disclosed introduce controlled number of phenylboronic acid (PBA) moieties into telodendrimer (TD) nanoplatform for optimizing AmB conjugation via reversible boronate ester strategy. This multivalent flexible boronate TD nanoplatform can also be applied in developing prodrugs for different cis-diol containing or α- or β- hydroxyl ketone-containing drug molecules.
PCT/US2024/033004 2023-06-07 2024-06-07 Boronate prodrug nanoformulations in disease treatments Ceased WO2024254448A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363471669P 2023-06-07 2023-06-07
US63/471,669 2023-06-07

Publications (2)

Publication Number Publication Date
WO2024254448A2 WO2024254448A2 (en) 2024-12-12
WO2024254448A3 true WO2024254448A3 (en) 2025-01-30

Family

ID=93794615

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033004 Ceased WO2024254448A2 (en) 2023-06-07 2024-06-07 Boronate prodrug nanoformulations in disease treatments

Country Status (1)

Country Link
WO (1) WO2024254448A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5098417A (en) * 1990-04-12 1992-03-24 Ricoh Kyosan, Inc. Cellulosic wound dressing with an active agent ionically absorbed thereon
US20150045419A1 (en) * 2011-05-13 2015-02-12 The Regents Of The University Of California Reversibly crosslinked micelle systems
WO2021126970A1 (en) * 2019-12-17 2021-06-24 The Regents Of The University Of California Sequential targeting in crosslinking nano-theranostics for treating brain tumors
US20210346518A1 (en) * 2018-08-31 2021-11-11 The Regents Of The University Of California Cyanine-based telodendrimers and uses for treating cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5098417A (en) * 1990-04-12 1992-03-24 Ricoh Kyosan, Inc. Cellulosic wound dressing with an active agent ionically absorbed thereon
US20150045419A1 (en) * 2011-05-13 2015-02-12 The Regents Of The University Of California Reversibly crosslinked micelle systems
US20210346518A1 (en) * 2018-08-31 2021-11-11 The Regents Of The University Of California Cyanine-based telodendrimers and uses for treating cancer
WO2021126970A1 (en) * 2019-12-17 2021-06-24 The Regents Of The University Of California Sequential targeting in crosslinking nano-theranostics for treating brain tumors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHENG GUODONG, ZHENG JIAHUI, XIAO LE, SHANG TONGYI, CAI YANJUN, LI YUWEI, XU YIMING, CHEN XIAOMING, LIU YUN, YANG BIN: "Construction of a Phenylboronic Acid-Functionalized Nano-Prodrug for pH-Responsive Emodin Delivery and Antibacterial Activity", ACS OMEGA, ACS PUBLICATIONS, US, vol. 6, no. 12, 30 March 2021 (2021-03-30), US , pages 8672 - 8679, XP093271154, ISSN: 2470-1343, DOI: 10.1021/acsomega.1c00606 *

Also Published As

Publication number Publication date
WO2024254448A2 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
Hammond 3 biological activity of polyene antibiotics
MX9304485A (en) SOLID, ORAL, CONTROLLED RELEASE FORMULATION, INCLUDING AGGLOMERATED HYDROPHILIC COMPLEXES WITH MULTIPHASIC RELEASE CHARACTERISTICS.
WO2001062300A3 (en) Caspase activated prodrugs therapy
LV11430A (en) Compounds of 2-pyridylmethylenpoliazamacrocyclophosphonophores and their derivatives for use as a contrast agent
DK1248613T3 (en) Clonidine preparations
WO2006065392A3 (en) Cancer treatments
WO1999002186A3 (en) Antigen delivery system comprising monoglyceride or diglyceride derivatives as adjuvant
HK26584A (en) Injection solutions containing micelle-forming agents
ES2144039T3 (en) PROCEDURE AND DEVICE FOR THE ROLLING OF GLASS LEAVES.
ATE463261T1 (en) MENINGOCOCCAL CONJUGATE VACCINATION
WO2004111199A3 (en) Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
IL198783A0 (en) Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
WO2002015938A8 (en) Testosterone ester formulation for human use
ATE512670T1 (en) MENINGOCOCCAL CONJUGATE VACCINATION
DE69726712T2 (en) ISCOM OR ISCOM-MATRIX, WHICH CONTAINS ONE AGENT AGAINST THE MUCUTINE AND ANTIQUE
WO2024254448A3 (en) Boronate prodrug nanoformulations in disease treatments
WO2004112717A3 (en) Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof
WO2007064968A3 (en) Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate
WO2002043739A3 (en) Dermatological formulations containing clindamycin and a zinc-salt
WO2007044348A8 (en) Anti-infective hygiene products based on cellulose acetate phthalate
AU5487101A (en) Cosmetic or dermatological product comprising a freeze-dried hydrocolloid composition
WO2001051021A3 (en) Use of dehydroepiandrosterone or some derivatives thereof to improve papery aspect of the skin
AU7335300A (en) Treatment of fungal infections utilizing a fungal growth medium
WO2007092299A3 (en) Targeted conjugates and radiation
PT1878431E (en) Medicinal agent for preventing progression of apoptotic and jugulating necrotic changes in the organism tissues

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE